ArticleAdvances in therapy2026
Perspectives on Living with Relapsed/Refractory Multiple Myeloma and Multidisciplinary Care from a Patient, Nurse Practitioner, Dietitian, and a Patient Advocate.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma is a malignant hematologic disorder characterized by the proliferation of abnormal plasma cells in the bone marrow. Although improvements in survival as novel therapies have become available, almost all patients who receive multiple myeloma therapies will relapse. Patients experience physical and emotional impacts from both multiple myeloma and its treatment as they progress through periods of remission and relapse. It is essential to support patients throughout their disease with holistic management, underpinned by collaboration among the clinical team and emotional support resources, including access to patient support groups. This article is co-authored by a person living with multiple myeloma, along with a dietitian specializing in cancer dietetics, a nurse practitioner who cares for patients with multiple myeloma at a large academic center, and a patient advocate at the International Myeloma Foundation. Written from a first-person perspective, the patient describes her journey of living with multiple myeloma and her current treatment with talquetamab, with added perspectives from clinical and patient advocacy experts.
Indexed as
Identifiers
42804083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.